Last update 26 Nov 2024
Clifutinib Besylate
Last update 26 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms HEC-73543 |
Target |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
8
Clinical Trials associated with Clifutinib BesylateHEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial
HEC73543片治疗FLT3-ITD突变的复发/难治急性髓系白血病的随机、开放、挽救性化疗对照、多中心III期临床试验
[Translation] A randomized, open-label, salvage chemotherapy-controlled, multicenter phase III clinical trial of HEC73543 tablets in the treatment of relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation
A Food Effect Phase I Study of the Clifutinib in Healthy Subjects
100 Clinical Results associated with Clifutinib Besylate
Login to view more data
100 Translational Medicine associated with Clifutinib Besylate
Login to view more data
100 Patents (Medical) associated with Clifutinib Besylate
Login to view more data
100 Deals associated with Clifutinib Besylate
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia with FLT3/ITD Mutation | Phase 3 | CN | 27 Feb 2023 | |
| Adult Acute Myeloblastic Leukemia | Phase 2 | CN | 01 Oct 2022 | |
| Leukemia | Phase 1 | CN | 30 Jan 2022 | |
| Refractory acute myeloid leukemia | Phase 1 | CN | 18 May 2018 | |
| Relapsing acute myeloid leukemia | Phase 1 | CN | 18 May 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 75 | zkrdpymnvj(ulunjldnlw) = avdwggjvwa yzxynanfam (jkxdhxuhle ) View more | - | 11 Dec 2023 | |||
NCT04827069 (EHA2022) Manual  | Phase 1 | 53 | gxnhapqzmz(tsnjtazkfp) = pcklqhizzb rkqpremsus (vdzbaurlza ) View more | Positive | 12 May 2022 | ||
aqdjrpcoex(ginlxnuvmu) = ocbkbtsozx ftaxgxuint (hvvxtlajrh ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free